Esketamine, a nasal spray similar to ketamine, is set to become accessible for 30,000 Australians suffering from treatment-resistant depression through the Pharmaceutical Benefits Scheme. This medication acts on glutamate, distinguishing it from conventional antidepressants like Prozac, which target serotonin and take extended periods to work. Australian trials demonstrate significant improvements in about 50% of participants, presenting a novel therapeutic avenue where traditional treatments have failed. This move signifies a major advancement in the mental health landscape, marking the first governmental funding for a new depression treatment in three decades.
Spravato, also known as esketamine, targets glutamate and can produce rapid effects for those with treatment-resistant depression, offering hope where traditional antidepressants fail.
This marks the first new type of medicine for major depression to be funded by the Australian government in three decades, highlighting a significant innovation.
Collection
[
|
...
]